vs
WW INTERNATIONAL, INC.（WW）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
WW INTERNATIONAL, INC.的季度营收约是再鼎医药的1.4倍（$184.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs -4.5%），WW INTERNATIONAL, INC.自由现金流更多（$8.4M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs -7.4%）
WW国际前身为慧俪轻体国际，是一家总部位于美国的全球性企业，主营减重与体重管理、健身及心态调整相关服务，核心产品为慧俪轻体综合减重饮食方案。公司由纽约皇后区的家庭主妇珍·妮德奇于1963年创立，截至2019年，其服务包含手机应用及网站线上方案、线上或电话指导、线下见面会三种模式。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
WW vs ZLAB — 直观对比
营收规模更大
WW
是对方的1.4倍
$127.1M
营收增速更快
ZLAB
高出21.6%
-4.5%
自由现金流更多
WW
多$35.1M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
-7.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $184.3M | $127.1M |
| 净利润 | $-56.3M | — |
| 毛利率 | 72.2% | 51.0% |
| 营业利润率 | 5.8% | -54.6% |
| 净利率 | -30.5% | — |
| 营收同比 | -4.5% | 17.1% |
| 净利润同比 | -21.8% | — |
| 每股收益（稀释后） | $-5.63 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收WWZLAB
| Q4 25 | — | $127.1M | ||
| Q3 25 | $184.3M | $115.4M | ||
| Q2 25 | — | $109.1M | ||
| Q1 25 | $186.6M | $105.7M | ||
| Q4 24 | $184.4M | $108.5M | ||
| Q3 24 | $192.9M | $101.8M | ||
| Q2 24 | $202.1M | $100.1M | ||
| Q1 24 | $206.5M | $87.1M |
净利润WWZLAB
| Q4 25 | — | — | ||
| Q3 25 | $-56.3M | $-36.0M | ||
| Q2 25 | — | $-40.7M | ||
| Q1 25 | $-72.6M | $-48.4M | ||
| Q4 24 | $25.1M | — | ||
| Q3 24 | $-46.2M | $-41.7M | ||
| Q2 24 | $23.3M | $-80.3M | ||
| Q1 24 | $-347.9M | $-53.5M |
毛利率WWZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | 72.2% | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | 71.2% | 63.6% | ||
| Q4 24 | 69.7% | 61.5% | ||
| Q3 24 | 67.1% | 64.1% | ||
| Q2 24 | 67.9% | 64.9% | ||
| Q1 24 | 66.7% | 61.4% |
营业利润率WWZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | 5.8% | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | -10.8% | -53.3% | ||
| Q4 24 | 19.6% | -62.6% | ||
| Q3 24 | -20.2% | -66.6% | ||
| Q2 24 | 17.8% | -76.0% | ||
| Q1 24 | -130.4% | -80.7% |
净利率WWZLAB
| Q4 25 | — | — | ||
| Q3 25 | -30.5% | -31.2% | ||
| Q2 25 | — | -37.3% | ||
| Q1 25 | -38.9% | -45.8% | ||
| Q4 24 | 13.6% | — | ||
| Q3 24 | -23.9% | -40.9% | ||
| Q2 24 | 11.5% | -80.2% | ||
| Q1 24 | -168.4% | -61.4% |
每股收益（稀释后）WWZLAB
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $-5.63 | $-0.03 | ||
| Q2 25 | — | $-0.04 | ||
| Q1 25 | $-0.91 | $-0.04 | ||
| Q4 24 | $0.34 | $-0.09 | ||
| Q3 24 | $-0.58 | $-0.04 | ||
| Q2 24 | $0.29 | $-0.08 | ||
| Q1 24 | $-4.39 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $323.0M | $715.5M |
| 总资产 | $968.8M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资WWZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | $170.1M | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | $236.3M | $757.3M | ||
| Q4 24 | $53.0M | $779.7M | ||
| Q3 24 | $57.2M | $616.1M | ||
| Q2 24 | $42.7M | $630.0M | ||
| Q1 24 | $66.6M | $650.8M |
总债务WWZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益WWZLAB
| Q4 25 | — | $715.5M | ||
| Q3 25 | $323.0M | $759.9M | ||
| Q2 25 | — | $791.7M | ||
| Q1 25 | $-1.2B | $810.8M | ||
| Q4 24 | $-1.1B | $840.9M | ||
| Q3 24 | $-1.1B | $667.7M | ||
| Q2 24 | $-1.1B | $704.2M | ||
| Q1 24 | $-1.1B | $762.2M |
总资产WWZLAB
| Q4 25 | — | $1.2B | ||
| Q3 25 | $968.8M | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | $696.9M | $1.2B | ||
| Q4 24 | $550.3M | $1.2B | ||
| Q3 24 | $562.4M | $985.3M | ||
| Q2 24 | $614.3M | $987.4M | ||
| Q1 24 | $654.2M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $8.4M | $-26.7M |
| 自由现金流率自由现金流/营收 | 4.6% | -21.0% |
| 资本支出强度资本支出/营收 | 0.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $44.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流WWZLAB
| Q4 25 | — | $-26.0M | ||
| Q3 25 | $8.4M | $-32.0M | ||
| Q2 25 | — | $-31.0M | ||
| Q1 25 | $15.0M | $-61.7M | ||
| Q4 24 | $4.6M | $-55.8M | ||
| Q3 24 | $16.5M | $-26.8M | ||
| Q2 24 | $-1.9M | $-42.2M | ||
| Q1 24 | $-36.0M | $-90.1M |
自由现金流WWZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | $8.4M | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | $15.0M | $-63.2M | ||
| Q4 24 | $4.5M | $-58.4M | ||
| Q3 24 | $16.4M | $-28.2M | ||
| Q2 24 | $-2.2M | $-42.9M | ||
| Q1 24 | $-36.5M | $-91.1M |
自由现金流率WWZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | 4.6% | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | 8.0% | -59.9% | ||
| Q4 24 | 2.4% | -53.8% | ||
| Q3 24 | 8.5% | -27.7% | ||
| Q2 24 | -1.1% | -42.9% | ||
| Q1 24 | -17.7% | -104.5% |
资本支出强度WWZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | 0.0% | 1.5% | ||
| Q4 24 | 0.1% | 2.4% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.2% | 1.1% |
现金转化率WWZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.18× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.08× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
WW
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
